BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31846507)

  • 1. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
    Goossens N; Bellentani S; Cerny A; Dufour JF; Jornayvaz FR; Mertens J; Moriggia A; Muellhaupt B; Negro F; Razavi H; Semela D; Estes C
    Swiss Med Wkly; 2019 Dec; 149():w20152. PubMed ID: 31846507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
    Adams LA; Roberts SK; Strasser SI; Mahady SE; Powell E; Estes C; Razavi H; George J
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1628-1635. PubMed ID: 32048317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
    Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.
    Swain MG; Ramji A; Patel K; Sebastiani G; Shaheen AA; Tam E; Marotta P; Elkhashab M; Bajaj HS; Estes C; Razavi H
    CMAJ Open; 2020; 8(2):E429-E436. PubMed ID: 32518095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
    Kaya E; Yılmaz Y
    Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors of fatty liver in Portuguese adults.
    Leitão J; Carvalhana S; Cochicho J; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Oliveiros B; Rodrigues V; Sousa R; Sampaio F; Carvalho A; Cortez-Pinto H
    Eur J Clin Invest; 2020 Jun; 50(6):e13235. PubMed ID: 32289180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Younossi Z; Tacke F; Arrese M; Chander Sharma B; Mostafa I; Bugianesi E; Wai-Sun Wong V; Yilmaz Y; George J; Fan J; Vos MB
    Hepatology; 2019 Jun; 69(6):2672-2682. PubMed ID: 30179269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
    Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
    Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.